Recently, monoclonal antibodies used in immunotherapy for the treatment of cancer have demonstrated clinical success, particularly when used with the antigens programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1). D dostarlimab inhibits PD-L1 and PD-L2 interactions as well as exchange with adaptive immunity by binding to human PD-1. A s a result of recent clinical trials demonstrating that it is successful in treating mismatch repair deficiency (dMMR) in patients with endometrial cancer, Dostarlimab gets authorised in the United States and the European Union in 2021 . This article provides an exhaustive overview of dostarlimab, its therapeutic effect, and its promising applications. Dostarlimab could be a suitable replacement for umpteen cancer treatments, which frequently have detrimental impact on patients' lives